Cart
sales@molnova.com
Vopratelimab
CAS No. 2039148-04-2
Vopratelimab( —— )
Catalog No. M36893 CAS No. 2039148-04-2
Vopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody and a potent ICOS agonist with high affinity for inducible T cell co-stimulating factors (ICOS), showing affinities of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1017 | In Stock |
|
| 10MG | 1568 | In Stock |
|
| 25MG | 2337 | In Stock |
|
| 50MG | 3088 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVopratelimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionVopratelimab (JTX-2011) is a selective humanized immunoglobulin G1-kappa monoclonal antibody and a potent ICOS agonist with high affinity for inducible T cell co-stimulating factors (ICOS), showing affinities of 0.93 nM for hICOS, 3.7 nM for rat ICOS, and 0.64 nM for mICOS.
-
DescriptionVopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response.
-
In Vitro——
-
In VivoAnimal Model:Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model Dosage:0.25-0.3 mg/kg Administration:Intraperitoneal injection; twice a week, for 2 weeks Result:Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2039148-04-2
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hanson A, et, al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS One. 2020 Sep 24;15(9):e0239595.?
molnova catalog
related products
-
SB-216
SB-216 is able to be used for the research of cancer which is a potent inhibitor of tubulin polymerization.
-
2′,2′-Difluorodeoxyu...
2′,2′-Difluorodeoxyuridine (dFdU), the major metabolite of Gemcitabine, exhibits anticancer and antitumor activities, shows radiosensitization under hypoxic conditions, and can be used to study pancreatic cancer.
-
2R,4S-Sacubitril
2R,4S-Sacubitril is the impurity of Sacubitril which is a neprilysin inhibitor.
